Article

FDA Panel Narrowly Rejects Xarelto for ACS

An FDA advisory committee has voted 6-4, with one abstention, against expanding the marketing indications for the factor Xa inhibitor rivaroxaban (Xarelto) to include treatment of acute coronary syndrome (ACS).

The vote by the Cardiovascular and Renal Drugs Advisory Committee was somewhat surprising given the positive review from FDA staff released two days before the meeting, but it signals a growing reluctance to expand indications based on data from a single trial.

Read the full story: http://hcp.lv/Kdov5I

Source: MedPage Today

Related Videos
Dr Duke Appiah
Ajai Chari, MD
Shawn Griffin, MD, sitting for a video interview
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
John Michael O'Brien, PharmD, MPH
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo